Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | December 2007 |
| End Date: | July 2008 |
| Contact: | Wendy Austin, MD |
| Email: | waustin@ucsd.edu |
| Phone: | 619-543-8213 |
The Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction
The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved
medication for the treatment of angina, on heart function by using echocardiography.
medication for the treatment of angina, on heart function by using echocardiography.
Inclusion Criteria:
- Moderate of severe diastolic dysfunction, E/Ea>12
- Preserved systolic function
- NYHA Class I-II
Exclusion Criteria:
- QTc >450 msec at enrollment
- Taking medications that prolong QT interval or are potent inhibitors of CYP3A
- Significant coronary artery disease
- Severe valvular disease
- Hepatic disease
- Severe kidney disease
- Women of childbearing age
- Prior serious ventricular arrhythmia
We found this trial at
1
site
Click here to add this to my saved trials
